The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of ACR-368 and low dose gemcitabine combination therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
 
Robin Park
Employment - Moffitt Cancer Center
 
Dan Zandberg
Consulting or Advisory Role - Bicara Therapeutics; Blueprint Medicines; Coherus Biosciences; Coherus Biosciences; InhibRx; Macrogenics; Merck; Prelude Therapeutics; Seagen
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); AVEO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)
 
Jean-Marie Cuillerot
Employment - Acrivon Therapeutics; Dragonfly Therapeutics
Leadership - Acrivon Therapeutics
Stock and Other Ownership Interests - Acrivon Therapeutics; Dragonfly Therapeutics
Consulting or Advisory Role - Domaine
 
Erick Gamelin
Employment - Acrivon Therapeutics
 
Satish Maharaj
Employment - Moffitt Cancer Center; Texas Tech University (I)
 
Kedar Kirtane
Leadership - MyCareGorithm
Stock and Other Ownership Interests - Agenus; Oncternal Therapeutics; Veru
Consulting or Advisory Role - MyCareGorithm
Research Funding - Turnstone Bio
Travel, Accommodations, Expenses - A2Bio
 
Guilherme Rabinowits
Consulting or Advisory Role - BioMedical Insights; BostonGene; Exelixis; Merck Serono; replimune; Sanofi/Regeneron
 
Christine Chung
Consulting or Advisory Role - AVEO; Bicara Therapeutics; Exelixis; Fulgent Pharma; Genmab; Johnson & Johnson/Janssen; Regeneron; Seagen
Research Funding - Acrivon Therapeutics (Inst); Regeneron (Inst)